These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38045493)

  • 1. Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort.
    Wang X; Meisel Z; Kellom K; Whitaker J; Strane D; Chatterjee A; Rosenquist R; Matone M
    Drug Alcohol Depend Rep; 2023 Dec; 9():100206. PubMed ID: 38045493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparities in opioid use disorder-related hospital use among postpartum Virginia Medicaid members.
    Martin CE; Britton E; Shadowen H; Bachireddy C; Harrell A; Zhao X; Cunningham P
    J Subst Use Addict Treat; 2023 Feb; 145():208935. PubMed ID: 36880911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of treatment for opioid use disorder among birthing people.
    Kim K; Liu G; Dick AW; Choi SW; Agbese E; Corr TE; Hsuan C; Wright MS; Park S; Velott D; Leslie DL
    J Subst Use Addict Treat; 2024 Jun; 161():209289. PubMed ID: 38272119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Severe Maternal Morbidity in Birthing People With Opioid Use Disorder.
    Osei-Poku GK; Prentice JC; Peeler M; Bernstein SN; Iverson RE; Schiff DM
    Womens Health Issues; 2023; 33(5):524-531. PubMed ID: 37423777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatric comorbidities and their treatment predict buprenorphine continuation among postpartum people with opioid use disorder.
    Shadowen H; Violante S; Gataric A; Goulding AN; Martin CE
    Drug Alcohol Depend Rep; 2022 Dec; 5():. PubMed ID: 36644222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
    Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
    N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postpartum medication for opioid use disorder outcomes associated with prenatal treatment and neighborhood-level social determinants.
    Martin CE; Britton E; Shadowen H; Johnson J; Sabo R; Cunningham P
    Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101173. PubMed ID: 37783277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Health Insurance, Geography, and Race and Ethnicity With Disparities in Receipt of Recommended Postpartum Care in the US.
    Interrante JD; Admon LK; Carroll C; Henning-Smith C; Chastain P; Kozhimannil KB
    JAMA Health Forum; 2022 Oct; 3(10):e223292. PubMed ID: 36239954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder.
    Tabatabaeepour N; Morgan JR; Jalali A; Kapadia SN; Meinhofer A
    J Subst Abuse Treat; 2022 Sep; 140():108800. PubMed ID: 35577664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery.
    Nielsen T; Bernson D; Terplan M; Wakeman SE; Yule AM; Mehta PK; Bharel M; Diop H; Taveras EM; Wilens TE; Schiff DM
    Addiction; 2020 Feb; 115(2):291-301. PubMed ID: 31692133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance.
    Mark TL; Hinde JM; Zarkin GA; Parish W; Kluckman M
    J Subst Abuse Treat; 2020 Sep; 116():108062. PubMed ID: 32741503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparities in receipt of medications for opioid use disorder among pregnant women.
    Henkhaus LE; Buntin MB; Henderson SC; Lai P; Patrick SW
    Subst Abus; 2022; 43(1):508-513. PubMed ID: 34270396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.